No Benefit, More Side Effects With Injectable Risperidone

Pin It

Long-acting, injectable risperidone, the first second-generation antipsychotic available in the United States in this formulation, is no better than oral antipsychotics for the treatment of unstable schizophrenia, a new study published in the March 3 issue of the New England Journal of Medicine suggests.

In a randomized study of more than 300 Veterans Affairs (VA) patients, investigators found injectable risperidone did not significantly decrease hospitalization rates or improve symptoms, social function, or quality of life compared with those treated with “clinicians’ choice” of oral antipsychotics. The risperidone-treated group also reported more adverse effects.

Reported by Deborah Brauser
Medscape Medical News
http://www.medscape.com/viewarticle/738331

Speak Your Mind

*